Concepts (269)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 45 | 2025 | 708 | 3.860 |
Why?
|
| Anti-HIV Agents | 23 | 2023 | 163 | 2.540 |
Why?
|
| Antiviral Agents | 8 | 2025 | 92 | 1.650 |
Why?
|
| HIV-1 | 14 | 2015 | 72 | 1.640 |
Why?
|
| Adenosine Monophosphate | 2 | 2025 | 6 | 1.080 |
Why?
|
| Alanine | 2 | 2025 | 8 | 1.080 |
Why?
|
| Home Care Services | 2 | 2025 | 35 | 0.960 |
Why?
|
| Pyridazines | 5 | 2010 | 6 | 0.850 |
Why?
|
| Adult | 50 | 2025 | 7255 | 0.840 |
Why?
|
| CD4 Lymphocyte Count | 20 | 2022 | 182 | 0.820 |
Why?
|
| Viral Load | 16 | 2018 | 141 | 0.810 |
Why?
|
| Reverse Transcriptase Inhibitors | 7 | 2013 | 29 | 0.750 |
Why?
|
| Male | 51 | 2025 | 9556 | 0.740 |
Why?
|
| Middle Aged | 42 | 2025 | 7515 | 0.710 |
Why?
|
| Humans | 64 | 2025 | 16832 | 0.700 |
Why?
|
| Antiretroviral Therapy, Highly Active | 11 | 2017 | 91 | 0.670 |
Why?
|
| Hepatitis C, Chronic | 7 | 2015 | 51 | 0.660 |
Why?
|
| Female | 50 | 2025 | 12193 | 0.660 |
Why?
|
| Electronics, Medical | 1 | 2018 | 3 | 0.540 |
Why?
|
| Hepacivirus | 7 | 2015 | 41 | 0.530 |
Why?
|
| Carbamates | 6 | 2015 | 7 | 0.510 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2017 | 58 | 0.500 |
Why?
|
| Sofosbuvir | 5 | 2015 | 5 | 0.490 |
Why?
|
| Cohort Studies | 21 | 2023 | 2396 | 0.470 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 4 | 2015 | 4 | 0.470 |
Why?
|
| Treatment Outcome | 19 | 2020 | 1098 | 0.460 |
Why?
|
| Aged | 23 | 2025 | 5901 | 0.440 |
Why?
|
| Hepatitis B | 3 | 2022 | 43 | 0.430 |
Why?
|
| California | 19 | 2018 | 2244 | 0.410 |
Why?
|
| Pyrrolidinones | 3 | 2014 | 4 | 0.410 |
Why?
|
| Hepatitis B Vaccines | 4 | 2023 | 44 | 0.410 |
Why?
|
| Electronic Health Records | 1 | 2018 | 702 | 0.370 |
Why?
|
| Liver Diseases | 1 | 2012 | 24 | 0.360 |
Why?
|
| Anti-Retroviral Agents | 6 | 2015 | 82 | 0.360 |
Why?
|
| Young Adult | 15 | 2018 | 2456 | 0.350 |
Why?
|
| Myocardial Infarction | 3 | 2022 | 215 | 0.340 |
Why?
|
| HIV Envelope Protein gp41 | 3 | 2010 | 4 | 0.340 |
Why?
|
| Peptide Fragments | 3 | 2010 | 29 | 0.330 |
Why?
|
| Raltegravir Potassium | 4 | 2018 | 9 | 0.320 |
Why?
|
| Retrospective Studies | 9 | 2025 | 2463 | 0.310 |
Why?
|
| Drug Resistance, Viral | 7 | 2015 | 12 | 0.310 |
Why?
|
| Life Expectancy | 2 | 2020 | 33 | 0.280 |
Why?
|
| Neoplasms | 4 | 2015 | 447 | 0.260 |
Why?
|
| Prenatal Care | 1 | 2008 | 123 | 0.250 |
Why?
|
| Exercise Therapy | 2 | 2019 | 71 | 0.250 |
Why?
|
| AIDS Dementia Complex | 2 | 2025 | 4 | 0.250 |
Why?
|
| Hospitalization | 4 | 2023 | 816 | 0.240 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2008 | 158 | 0.240 |
Why?
|
| RNA, Viral | 8 | 2015 | 66 | 0.240 |
Why?
|
| Ritonavir | 4 | 2010 | 15 | 0.240 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 167 | 0.230 |
Why?
|
| Incidence | 8 | 2025 | 1229 | 0.230 |
Why?
|
| HIV | 2 | 2017 | 25 | 0.230 |
Why?
|
| Sulfonamides | 4 | 2014 | 13 | 0.220 |
Why?
|
| Patient Satisfaction | 1 | 2025 | 186 | 0.210 |
Why?
|
| Dideoxynucleosides | 3 | 2016 | 8 | 0.210 |
Why?
|
| Physicians | 1 | 2025 | 114 | 0.210 |
Why?
|
| Risk Factors | 11 | 2016 | 3108 | 0.210 |
Why?
|
| Emergency Service, Hospital | 2 | 2019 | 393 | 0.200 |
Why?
|
| Adolescent | 8 | 2018 | 3464 | 0.200 |
Why?
|
| Vaccination | 3 | 2020 | 725 | 0.200 |
Why?
|
| Anaphylaxis | 1 | 2023 | 15 | 0.200 |
Why?
|
| Thrombosis | 1 | 2023 | 16 | 0.190 |
Why?
|
| Dementia | 1 | 2025 | 137 | 0.190 |
Why?
|
| Drug Therapy, Combination | 8 | 2015 | 104 | 0.190 |
Why?
|
| Fractures, Bone | 1 | 2023 | 92 | 0.190 |
Why?
|
| Genotype | 7 | 2015 | 198 | 0.190 |
Why?
|
| Lymphoma, AIDS-Related | 3 | 2011 | 18 | 0.190 |
Why?
|
| Risk | 3 | 2020 | 453 | 0.180 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2023 | 60 | 0.180 |
Why?
|
| Mutation | 3 | 2012 | 86 | 0.180 |
Why?
|
| Case-Control Studies | 5 | 2020 | 995 | 0.180 |
Why?
|
| Aged, 80 and over | 8 | 2025 | 1887 | 0.180 |
Why?
|
| Patient Compliance | 4 | 2014 | 262 | 0.180 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 1233 | 0.180 |
Why?
|
| Herpes Zoster | 1 | 2023 | 80 | 0.180 |
Why?
|
| HIV Protease Inhibitors | 3 | 2010 | 24 | 0.170 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 1204 | 0.170 |
Why?
|
| HIV Reverse Transcriptase | 2 | 2012 | 2 | 0.170 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2021 | 20 | 0.160 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2020 | 12 | 0.160 |
Why?
|
| Pyridines | 3 | 2010 | 8 | 0.160 |
Why?
|
| Oligopeptides | 3 | 2010 | 7 | 0.160 |
Why?
|
| HIV Protease | 2 | 2010 | 4 | 0.160 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2018 | 515 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 56 | 0.150 |
Why?
|
| African Continental Ancestry Group | 2 | 2016 | 117 | 0.150 |
Why?
|
| Mentoring | 1 | 2019 | 29 | 0.140 |
Why?
|
| Walking | 2 | 2019 | 82 | 0.140 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2018 | 99 | 0.130 |
Why?
|
| United States | 6 | 2025 | 3858 | 0.130 |
Why?
|
| Tablets | 1 | 2017 | 2 | 0.130 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2017 | 5 | 0.130 |
Why?
|
| Psoriasis | 1 | 2017 | 9 | 0.130 |
Why?
|
| Organophosphonates | 3 | 2014 | 7 | 0.130 |
Why?
|
| Adenine | 3 | 2014 | 8 | 0.130 |
Why?
|
| Heart Failure | 1 | 2022 | 403 | 0.130 |
Why?
|
| Pneumonia | 1 | 2017 | 47 | 0.120 |
Why?
|
| Pneumococcal Infections | 1 | 2016 | 43 | 0.120 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 489 | 0.120 |
Why?
|
| Quality of Life | 2 | 2019 | 477 | 0.120 |
Why?
|
| Darunavir | 3 | 2010 | 4 | 0.120 |
Why?
|
| Tenofovir | 4 | 2023 | 18 | 0.120 |
Why?
|
| Pneumococcal Vaccines | 1 | 2016 | 67 | 0.120 |
Why?
|
| Uridine Monophosphate | 1 | 2015 | 1 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2015 | 5 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2022 | 1186 | 0.110 |
Why?
|
| Fluorenes | 1 | 2015 | 5 | 0.110 |
Why?
|
| Drug Administration Schedule | 4 | 2020 | 94 | 0.110 |
Why?
|
| Coinfection | 1 | 2015 | 28 | 0.110 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 94 | 0.110 |
Why?
|
| Isoquinolines | 1 | 2014 | 1 | 0.110 |
Why?
|
| Imidazoles | 1 | 2014 | 4 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2015 | 54 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2011 | 26 | 0.110 |
Why?
|
| Prostate-Specific Antigen | 1 | 2014 | 64 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 262 | 0.100 |
Why?
|
| Continental Population Groups | 1 | 2015 | 255 | 0.100 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2013 | 3 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 185 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 2 | 2014 | 157 | 0.100 |
Why?
|
| Primary Health Care | 2 | 2021 | 693 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 268 | 0.100 |
Why?
|
| Registries | 3 | 2012 | 449 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 213 | 0.100 |
Why?
|
| Protease Inhibitors | 1 | 2012 | 6 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 196 | 0.090 |
Why?
|
| Health Maintenance Organizations | 3 | 2008 | 358 | 0.090 |
Why?
|
| Managed Care Programs | 1 | 2014 | 275 | 0.090 |
Why?
|
| Hepatitis B, Chronic | 1 | 2012 | 23 | 0.090 |
Why?
|
| Viremia | 1 | 2012 | 9 | 0.090 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2012 | 6 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 30 | 0.090 |
Why?
|
| Stroke | 1 | 2014 | 297 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2012 | 261 | 0.090 |
Why?
|
| Liver Cirrhosis | 3 | 2015 | 32 | 0.090 |
Why?
|
| Drug Combinations | 3 | 2015 | 42 | 0.080 |
Why?
|
| Needs Assessment | 1 | 2011 | 64 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 520 | 0.080 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 84 | 0.080 |
Why?
|
| Ethnic Groups | 2 | 2015 | 418 | 0.080 |
Why?
|
| Social Support | 3 | 2019 | 195 | 0.080 |
Why?
|
| Fanconi Syndrome | 1 | 2010 | 5 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 117 | 0.080 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2015 | 16 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 1058 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 110 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 155 | 0.070 |
Why?
|
| Alcoholism | 1 | 2012 | 235 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2017 | 104 | 0.070 |
Why?
|
| Delivery of Health Care | 1 | 2012 | 374 | 0.070 |
Why?
|
| Substance-Related Disorders | 1 | 2012 | 305 | 0.070 |
Why?
|
| AIDS Serodiagnosis | 1 | 2008 | 8 | 0.070 |
Why?
|
| Birth Certificates | 1 | 2008 | 24 | 0.070 |
Why?
|
| Lamivudine | 1 | 2008 | 1 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 317 | 0.070 |
Why?
|
| Hispanic Americans | 2 | 2015 | 350 | 0.070 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2008 | 45 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 2015 | 138 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2008 | 155 | 0.060 |
Why?
|
| Disease Progression | 2 | 2019 | 252 | 0.060 |
Why?
|
| Depressive Disorder | 1 | 2008 | 177 | 0.060 |
Why?
|
| Viral Nonstructural Proteins | 2 | 2015 | 2 | 0.060 |
Why?
|
| Atazanavir Sulfate | 3 | 2010 | 5 | 0.060 |
Why?
|
| Comorbidity | 2 | 2020 | 516 | 0.060 |
Why?
|
| Prevalence | 1 | 2025 | 785 | 0.050 |
Why?
|
| Rivaroxaban | 1 | 2023 | 8 | 0.050 |
Why?
|
| Mexican Americans | 1 | 2003 | 43 | 0.050 |
Why?
|
| Herpesvirus 3, Human | 1 | 2023 | 40 | 0.050 |
Why?
|
| Pregnancy | 1 | 2008 | 1555 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2023 | 62 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 12 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2006 | 353 | 0.050 |
Why?
|
| Outpatients | 1 | 2023 | 99 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2023 | 127 | 0.050 |
Why?
|
| Creatinine | 2 | 2014 | 67 | 0.040 |
Why?
|
| Child | 1 | 2008 | 2433 | 0.040 |
Why?
|
| Least-Squares Analysis | 2 | 2012 | 12 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2017 | 1047 | 0.040 |
Why?
|
| Anus Neoplasms | 2 | 2012 | 28 | 0.040 |
Why?
|
| Medication Adherence | 2 | 2015 | 235 | 0.040 |
Why?
|
| Age Factors | 2 | 2014 | 814 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 44 | 0.040 |
Why?
|
| Immunization Programs | 1 | 2020 | 65 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 12 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 2010 | 67 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 36 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 2020 | 127 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2020 | 167 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 289 | 0.030 |
Why?
|
| Self Report | 1 | 2019 | 248 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 382 | 0.030 |
Why?
|
| Los Angeles | 2 | 2011 | 139 | 0.030 |
Why?
|
| Serogroup | 1 | 2016 | 11 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 2016 | 21 | 0.030 |
Why?
|
| Vaccines, Conjugate | 1 | 2016 | 59 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 97 | 0.030 |
Why?
|
| Ribavirin | 1 | 2015 | 6 | 0.030 |
Why?
|
| Spirometry | 1 | 2015 | 53 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2015 | 68 | 0.030 |
Why?
|
| Mass Screening | 1 | 2021 | 670 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 164 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 149 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 221 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 110 | 0.030 |
Why?
|
| Motivation | 1 | 2015 | 103 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 191 | 0.030 |
Why?
|
| International Cooperation | 1 | 2014 | 9 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 81 | 0.030 |
Why?
|
| Emtricitabine | 1 | 2014 | 1 | 0.030 |
Why?
|
| Cobicistat | 1 | 2014 | 1 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 2014 | 6 | 0.030 |
Why?
|
| Quinolones | 1 | 2014 | 4 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 186 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2014 | 6 | 0.030 |
Why?
|
| Thiazoles | 1 | 2014 | 10 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2014 | 7 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 14 | 0.030 |
Why?
|
| Hepatitis B virus | 1 | 2014 | 22 | 0.030 |
Why?
|
| Motor Activity | 1 | 2015 | 196 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 2014 | 24 | 0.030 |
Why?
|
| Gonorrhea | 1 | 2014 | 20 | 0.030 |
Why?
|
| Syphilis | 1 | 2014 | 18 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2015 | 400 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2013 | 11 | 0.020 |
Why?
|
| Genotyping Techniques | 1 | 2013 | 24 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 653 | 0.020 |
Why?
|
| Aging | 1 | 2014 | 146 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 657 | 0.020 |
Why?
|
| SEER Program | 1 | 2012 | 86 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 31 | 0.020 |
Why?
|
| Nucleosides | 1 | 2012 | 1 | 0.020 |
Why?
|
| Zidovudine | 1 | 2012 | 1 | 0.020 |
Why?
|
| Thymidine | 1 | 2012 | 2 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 560 | 0.020 |
Why?
|
| Virus Replication | 1 | 2011 | 14 | 0.020 |
Why?
|
| Phenotype | 1 | 2012 | 105 | 0.020 |
Why?
|
| Genomics | 1 | 2012 | 54 | 0.020 |
Why?
|
| Patient Advocacy | 1 | 2011 | 12 | 0.020 |
Why?
|
| Insurance Benefits | 1 | 2011 | 12 | 0.020 |
Why?
|
| African Americans | 1 | 2014 | 394 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 925 | 0.020 |
Why?
|
| Pyrones | 1 | 2010 | 1 | 0.020 |
Why?
|
| Saquinavir | 1 | 2010 | 1 | 0.020 |
Why?
|
| Lopinavir | 1 | 2010 | 5 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2010 | 5 | 0.020 |
Why?
|
| Indinavir | 1 | 2010 | 6 | 0.020 |
Why?
|
| Nelfinavir | 1 | 2010 | 4 | 0.020 |
Why?
|
| Exanthema | 1 | 2010 | 6 | 0.020 |
Why?
|
| Organophosphates | 1 | 2010 | 20 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 211 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 60 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2010 | 26 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 210 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 21 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 571 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 55 | 0.020 |
Why?
|
| Prognosis | 1 | 2010 | 568 | 0.020 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2007 | 1 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2008 | 210 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 989 | 0.020 |
Why?
|
| Medical Indigency | 1 | 2006 | 4 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 569 | 0.020 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2006 | 77 | 0.010 |
Why?
|
| Logistic Models | 1 | 2008 | 796 | 0.010 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2003 | 3 | 0.010 |
Why?
|
| Mexico | 1 | 2003 | 16 | 0.010 |
Why?
|
| Life Style | 1 | 2003 | 305 | 0.010 |
Why?
|
Concepts
(269)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(27)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->